



Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

Date: November 19, 2025

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051, Maharashtra, India.

NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013

Subject: Intimation of Award of Tender by Rajasthan Medical Services Corporation Limited

Regulation: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that **Zenith Drugs Limited** has been declared **L1 and successful bidder** for two key dermatological products under the tender floated by *Rajasthan Medical Services Corporation Limited (RMSCL)*.

The details of the products awarded are as follows:

1. Betamethasone Dipropionate Cream IP 0.05%

- Quantity: **44,78,711 units** (15 gm tube in unit carton)
- Total Value: **Rs. 2,11,10,663**

2. Fusidic Acid Cream IP 2%

- Quantity: **83,31,006 units** (10 gm tube in mono carton)
- Total Value: **Rs. 13,06,88,491**

Securing this tender reinforces the Company's strong presence in institutional supply channels and reflects the consistent confidence of government procurement agencies in our product quality, manufacturing capability, and service standards.

This is for your information and records.

Thank you.

For Zenith Drugs Limited

Sakshi Bhawsar
Company Secretary & Compliance Officer